Pretreatment proliferation parameters do not add predictive power to clinical factors in cervical cancer treated with definitive radiation therapy

Clinical Cancer Research

Volumn 9, Issue 12, 2003, Pages 4387-4395

  Tsang, Richard W ^a   Juvet, Stephen ^a   Pintilie, Melania ^a   Hill, Richard P ^a   Wong, C Shun ^b   Milosevic, Michael ^a   Chapman, William ^a   Fyles, Anthony W ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BROXURIDINE; HEMOGLOBIN;

ADULT; APOPTOSIS; ARTICLE; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER STAGING; CELL PROLIFERATION; FEMALE; FLOW CYTOMETRY; HEMOGLOBIN DETERMINATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MORPHOLOGY; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RELAPSE; SURVIVAL RATE; TISSUE SECTION; TREATMENT OUTCOME; TUMOR VOLUME; UTERINE CERVIX CANCER;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; BROMODEOXYURIDINE; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, SQUAMOUS CELL; CELL DIVISION; DISEASE-FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; RADIATION-SENSITIZING AGENTS; SURVIVAL RATE; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 0141995082     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Perez, C. A. Uterine cervix. In: C. A. Perez and L. W. Brady (eds.), Principles and Practice of Radiation Oncology, Ed. 3, pp. 1733-1834. Philadelphia: Lippincott-Raven Publishers, 1998.
2. Withers, H. R., Taylor, J. M. G., and Maciejewski, B. The hazard of accelerated tumour clonogen repopulation during radiotherapy. Acta Oncologica, 27: 131-146, 1988.
3. Fowler, J. F., and Lindstrom, M. J. Loss of local control with prolongation in radiotherapy. Int. J. Radiat. Oncol. Biol. Phys., 23: 457-467, 1992.
4. Begg, A. C., Hofland, I., Van Glabekke, M., Bartelink, H., and Horiot, J. C. Predictive value of potential doubling time for radiotherapy of head and neck tumor patients: results from the EORTC cooperative trial 22851. Semin. Radiat. Oncol., 2: 22-25, 1992.
5. Wilson, G. D., Dische, S., and Saunders, M. I. Studies with bromodeoxyuridine in head and neck cancer and accelerated radiotherapy. Radiother. Oncol., 36: 189-197, 1995.
6. Girinsky, T., Rey, A., Roche, B., Haie, C., Gerbaulet, A., Randrianarivello, H., and Chassagne, D. Overall treatment time in advanced cervical carcinomas: a critical parameter in treatment outcome. Int. J. Radiat. Oncol. Biol. Phys., 27: 1051-1056, 1993.
7. Fyles, A., Keane, T. J., Barton, M., and Simm, J. The effect of treatment duration in the local control of cervix cancer. Radiother. Oncol., 25: 273-279, 1992.
8. Lanciano, R. M., Pajak, T. F., Martz, K., and Hanks, G. E. The influence of treatment time on outcome for squamous cell cancer of the uterine cervix treated with radiation: a patterns-of-care study. Int. J. Radiat. Oncol. Biol. Phys., 25: 391-397, 1993.
9. Perez, C. A., Grigsby, P. W., Castro-Vita, H., and Lockett, M. A. Carcinoma of the uterine cervix. I. Impact of prolongation of overall treatment time and timing of brachytherapy on outcome of radiation therapy. Int. J. Radiat. Oncol. Biol. Phys., 32: 1275-1288, 1995.
10. pot in cancer of the uterine cervix: preliminary results. Int. J. Radiat. Oncol. Biol. Phys., 32: 1319-1329, 1995.
11. Wilson, G. D. Assessment of human tumor proliferation using bromodeoxyuridine-current status. Acta Oncologica, 30: 903-910, 1991.
12. Tucker, S. L., and Chan, K. S. The selection of patients for accelerated radiotherapy on the basis of tumor growth kinetics and radiosensitivity. Radiother. Oncol., 18: 197-211, 1990.
13. Saunders, M. I., Hoskin, P. J., Pigott, K., Powell, M. E., Goodchild, K., Dische, S., Denekamp, J., Stratford, M. R., Dennis, M. F., and Rojas, A. M. Accelerated radiotherapy, carbogen and nicotinamide (ARCON) in locally advanced head and neck cancer: a feasibility study. Radiother. Oncol., 45: 159-166, 1997.
14. Thames, H. D., Peters, L. J., Withers, H. R., and Fletcher, G. H. Accelerated fractionation vs hyperfractionation: Rationales for several treatments per day. Int. J. Radiat. Oncol. Biol. Phys., 9: 127-138, 1983.
15. Trott, K. R., and Kummermehr, J. What is known about tumour proliferation rates to choose between accelerated fractionation or hyperfractionation? Radiother. Oncol., 3: 1-9, 1985.
16. Tsang, R. W., Wong, C. S., Fyles, A. W., Levin, W., Manchul, L. A., Milosevic, M., Chapman, W., Li, Y. Q., and Pintilie, M. Tumour proliferation and apoptosis in human uterine cervix carcinoma II: correlations with clinical outcome. Radiother. Oncol., 50: 93-101, 1999.
17. Tsang, R. W., Fyles, A. W., Li, Y., Rajaraman, M. M., Chapman, W., Pintilie, M., and Wong, C. S. Tumor proliferation and apoptosis in human uterine cervix carcinoma I: correlations between variables. Radiother. Oncol., 50: 85-92, 1999.
18. Bolger, B. S., Symonds, R. P., Stanton, P. D., MacLean, A. B., Burnett, R., Kelly, P., and Cooke, T. G. Prediction of radiotherapy response of cervical carcinoma through measurement of proliferation rate. Br. J. Cancer, 74: 1223-1226, 1996.
19. Bennett, M. H., Wilson, G. D., Dische, S., Saunders, M. I., Martindale, C. A., Robinson, B. M., O'Halloran, A. E., Leslie, M. D., and Laing, J. H. E. Tumour proliferation assessed by combined histological and flow cytometric analysis: implications for therapy in squamous cell carcinoma in the head and neck. Br. J. Cancer, 65: 870-878, 1992.
20. Fyles, A., Milosevic, M., Hedley, D., Pintilie, M., Levin, W., Manchul, L., and Hill, R. P. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J. Clin. Oncol., 20: 680-687, 2002.
21. Milosevic, M., Fyles, A., Hedley, D., Pintilie, M., Levin, W., Manchul, L., and Hill, R. Interstitial fluid pressure predicts survival in patients with cervix cancer independent of clinical prognostic factors and tumor oxygen measurements. Cancer. Res., 61: 6400-6405, 2001.
22. Tsang, R. W., Fyles, A. W., Milosevic, M., Syed, A., Pintilie, M., Levin, W., and Manchul, L. A. Interrelationship of proliferation and hypoxia in carcinoma of the cervix. Int. J. Radiat. Oncol. Biol. Phys., 46: 95-99, 2000.
23. Hill, R. P., Fyles, A. W., Milosevic, M., Pintilie, M., and Tsang, R. W. Is there a relationship between repopulation and hypoxia/reoxygenation? Results from human carcinoma of the cervix. Int. J. Radiat. Biol., in press, 2003.
24. Pitson, G., Fyles, A., Milosevic, M., Wylie, J., Pintilie, M., and Hill, R. Tumor size and oxygenation are independent predictors of nodal diseases in patients with cervix cancer. Int. J. Radiat. Oncol. Biol. Phys., 51: 699-703, 2001.
25. Kaplan, E. L., and Meier, P. Non-parametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
26. Kalbfleisch, J., and Prentice, R. (eds.). The Statistical Analysis of Failure Time Data. New York: John Wiley & Sons, 1980.
27. Cox, D. R. Regression models and lifetables. J. Royal Stat. Soc., 34: 187-202, 1972.
28. Steel, G. G. Growth kinetics of tumours. Oxford: Clarendon Press, 1977.
29. Begg, A. C., McNally, N. J., Shrieve, D. C., and Karcher, H. A method to measure the duration of DNA synthesis and the potential doubling time from a single sample. Cytometry, 6: 620-626, 1985.
30. Begg, A. C. Critical appraisal of in situ cell kinetic measurements as response predictors in human tumors. Semin. Radiat. Oncol., 3: 144-151, 1993.
31. Haustermans, K., Hofland, I., Ramaekers, M., Ivanyi, D., Balm, A. J. M., Geboes, K., Lerut, T., van der Schueren, E., and Begg, A. C. Enrichment of tumor cells for cell kinetic analysis in human tumor biopsies using cytokeratin gating. Radiother. Oncol., 41: 237-248, 1996.
32. Cole, D. J., Brown, D. C., Crossley, E., Alcock, C. J., and Gatter, K. C. Carcinoma of the cervix uteri: an assessment of the relationship of tumour proliferation to prognosis. Br. J. Cancer, 65: 783-785, 1992.
33. Oka, K., and Arai, T. MIBI growth fraction is not related to prognosis in cervical squamous cell carcinoma treated with radiotherapy. Int. J. Gynecol. Pathol., 15: 23-27, 1996.
34. Oka, K., Hoshi, T., and Arai, T. Prognostic significance of the PC10 index as a prospective assay for cervical cancer treated with radiation therapy alone. Cancer (Phila.), 70: 1545-1550, 1992.
35. Bergstrom, C., Begg, A., Palmqvist, R., Waites, A., and Denekamp, J. Labelling indices in human tumours: to apply corrections or not-that is the question. Br. J. Cancer, 80: 1635-1643, 1999.
36. Haustermans, K., and Fowler, J. F. Is there a future for cell kinetic measurements using IdUrd or BdUrd? Int. J. Radiat. Oncol. Biol. Phys., 49: 505-511, 2001.
37. Nakano, T., and Oka, K. Differential values of Ki-67 index and mitotic index of proliferating cell population. An assessment of cell cycle and prognosis in radiation therapy for cervical cancer. Cancer (Phila.), 72: 2401-2408, 1993.
38. Bar, J. K., Harlozinska, A., Markowska, J., and Nowak, M. Studies on tumor proliferation using monoclonal antibody, Ki 67 and expression of p53 in cancer of the uterine cervix. Eur. J. Gynaecol. Oncol., 17: 378-380, 1996.
39. Wong, F. W. Immunohistochemical detection of proliferating tumor cells in cervical cancer using monoclonal antibody Ki-67. Gynecol. Obstet. Investig., 37: 123-126, 1994.
40. Nakano, T., Oka, K., Ishikawa, A., and Morita, S. Immunohistochemical prediction of radiation response and local control in radiation therapy for cervical cancer. Cancer Detect. Prev., 22: 120-128, 1998.
41. Costa, S., Terzano, P., Santini, D., Ceccarelli, C., Martoni, A., Angelelli, B., Panetta, A., Bovicelli, A., Cristiani, P., Lipponen, P., Erzen, M., Syrjanen, S., and Syrjanen, K. Neoadjuvant chemotherapy in cervical carcinoma: regulators of cell cycle, apoptosis, and proliferation as determinants of response to therapy and disease outcome. Am. J. Clin. Pathol., 116: 729-737, 2001.
42. Pillai, M. R., Jayaprakash, P. G., and Nair, M. K. Tumour-proliferative fraction and growth factor expression as markers of tumour response to radiotherapy in cancer of the uterine cervix. J. Cancer Res. Clin. Oncol., 124: 456-461, 1998.
43. Graflund, M., Sorbe, B., Bryne, M., and Karlsson, M. The prognostic value of a histologic grading system, DNA profile, and MIB-1 expression in early stages of cervical squamous cell carcinomas. Int. J. Gynecol. Cancer, 12: 149-157, 2002.
44. Garzetti, G. G., Ciavattini, A., Lucarini, G., Goteri, G., de Nictolis, M., Muzzioli, M., Fabris, N., Romanini, C., and Biagini, G. MIB 1 immunostaining in stage I squamous cervical carcinoma: relationship with natural killer cell activity. Gynecol. Oncol., 58: 28-33, 1995.
45. Levine, E. L., Renehan, A., Gossiel, R., Davidson, S. E., Roberts, S. A., Chadwick, C., Wilks, D. P., Potten, C. S., Hendry, J. H., Hunter, R. D., and West, C. M. L. Apoptosis, intrinsic radiosensitivity and prediction of radiotherapy in cervical carcinoma. Radiother. Oncol., 37: 1-9, 1995.
46. Oka, K., Nakano, T., and Hoshi, T. Transient increases of growth fraction during fractionated radiation therapy for cervical carcinoma. Cancer (Phila.), 72: 2621-2627, 1993.
47. Oka, K., Suzuki, Y., and Nakano, T. High growth fraction at 9 grays of radiotherapy is associated with a good prognosis for patients with cervical squamous cell carcinoma. Cancer (Phila.), 89: 1526-1531, 2000.
48. Begg, A. C., Haustermans, K., Hart, A. A., Dische, S., Saunders, M., Zackrisson, B., Gustaffson, H., Coucke, P., Paschoud, N., Hoyer, M., Overgaard, J., Antognoni, P., Richetti, A., Bourhis, J., Bartelink, H., Horiot, J. C., Corvo, R., Giaretti, W., Awwad, H., Shouman, T., Jouffroy, T., Maciorowski, Z., Dobrowsky, W., Struikmans, H., Wilson, G. D., et al. The value of pretreatment cell kinetic parameters as predictors for radiotherapy outcome in head and neck cancer: a multicenter analysis. Radiother. Oncol., 50: 13-23, 1999.
49. Fyles, A. W., Milosevic, M., Wong, R., Kavanagh, M. C., Pintilie, M., Sun, A., Chapman, W., Levin, W., Manchul, L., Keane, T. J., and Hill, R. P. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother. Oncol., 48: 149-156, 1998.
50. Cooper, R. A., Wilks, D. P., Logue, J. P., Davidson, S. E., Hunter, R. D., Roberts, S. A., and West, C. M. High tumor angiogenesis is associated with poorer survival in carcinoma of the cervix treated with radiotherapy. Clin Cancer Res., 4: 2795-2800, 1998.
51. West, C. M., Davidson, S. E., Roberts, S. A., and Hunter, R. D. The independence of intrinsic radiosensitivity as a prognostic factor for patient response to radiotherapy of carcinoma of the cervix. Br. J. Cancer, 76: 1184-1190, 1997.
52. Paxton, J. R., Bolger, B. S., Armour, A., Symonds, R. P., Mao, J. H., and Burnett, R. A. Apoptosis in cervical squamous carcinoma: predictive value for survival following radiotherapy. J. Clin. Pathol., 53: 197-200, 2000.
53. Wheeler, J. A., Stephens, L. C., Tornos, C., Eiffel, P. J., Ang, K. K., Milas, L., Allen, P. K., and Meyn, R. E. ASTRO research fellowhsip: apoptosis as a predictor of tumor response to radiation in Stage IB cervical carcinoma. Int. J. Radiat. Oncol. Biol. Phys., 32: 1487-1493, 1995.
54. Chung, E. J., Seong, J., Yang, W. I., Park, T. K., Kim, J. W., Suh, C. O., and Kim, G. E. Spontaneous apoptosis as a predictor of radiotherapy in patients with stage IIB squamous cell carcinoma of te uterine cervix. Acta Oncol., 38: 449-454, 1999.